ArticleAnnals of surgery1994
Expression of the neurotensin gene in fetal human liver and fibrolamellar carcinoma.
Article in Annals of surgery, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 37 citations in OpenAlex.
- Procalcitonin as a potential tumor marker for fibrolamellar hepatocellular carcinoma: Insights from three patients and a literature review.Frontiers in medicine · 2026Article
- Neurotensin and Its Involvement in Female Hormone-Sensitive Cancers.International journal of molecular sciences · 2024Review
- Neurotensin and Its Involvement in Reproductive Functions: An Exhaustive Review of the Literature.International journal of molecular sciences · 2023Review
- Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event.World journal of gastrointestinal oncology · 2022Review
- Neurotensin as a source of cyclic AMP and co-mitogen in fibrolamellar hepatocellular carcinoma.Oncotarget · 2019Article
- Genome and transcriptome profiling of fibrolamellar hepatocellular carcinoma demonstrates p53 and IGF2BP1 dysregulation.PloS one · 2017Article
- Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma.Pediatric blood & cancer · 2016Review
- Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments.World journal of surgical oncology · 2016Review
- The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients.Oncotarget · 2015Article
- Pituitary protein 7B2 plasma levels in patients with liver disease: Comparisons with other hormones and neuropeptides.Oncology letters · 2013Article
- Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy.Frontiers in endocrinology · 2012Article
- Fibrolamellar carcinoma: 2012 update.Scientifica · 2012Review
- Article
- Characterization of early developmental pattern of expression of neurotensin/neuromedin N gene in foregut and midgut.Digestive diseases and sciences · 1999Article
- Fetal and neoplastic expression of the neurotensin gene in the human colon.Annals of surgery · 1996Article
- Primary Liver Cancers-Part 1: Histopathology, Differential Diagnoses, and Risk Stratification.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThis study determined whether the neurotensin gene (NT/N) is expressed in the normal adult liver and focal nodular hyperplasia (FNH) and confirmed NT/N expression in fibrolamellar carcinoma; whether NT/N or the neurotensin receptor is expressed in the fetal liver; and whether hepatic resection leads to expression of NT/N. SUMMARY BACKGROUND DATA: Neurotensin (NT), a gut tridecapeptide localized in the gastrointestinal tract of the adult to the small bowel, is an important hormone-regulating gut motility, secretion, and mucosal growth. Expression of the NT/N gene has been identified in fibrolamellar carcinomas, but NT/N is not known to be expressed in the normal liver.
methodsSensitive ribonuclease (RNase) protection assays were used to determine whether NT/N is expressed in fibrolamellar carcinoma, FNH, or healthy fetal and adult livers. The authors also determined whether the receptor for NT was present in the fetal liver and whether liver resection and subsequent regeneration could lead to re-expression of NT/N in the rat.
resultsNeurotensin is expressed in fibrolamellar carcinoma and in the fetal human liver, but not in the adult liver or the samples of FNH. In addition, the authors were not able to detect expression of the NT receptor in the fetal liver and did not identify NT/N gene activation in the regenerating liver of the rat.
conclusionsThe NT/N gene will be a useful molecular marker to differentiate fibrolamellar carcinoma from other liver tumors. The finding of NT/N expression in the fetal liver suggests a stem cell descendant that is common to both the liver and gut. The absence of NT/N expression in the regenerating liver suggests that NT does not play a role in this rapid growth process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.